Vitamin D plus calcium supplementation was associated with a 50% reduction in hip BMD loss 48 weeks after initiation of efavirenz/emtricitabine/tenofovir DF in treatment-naive patients.
Interim analysis finds no cases of linked HIV transmissions despite high levels of condomless sex.
Interferon-free, all-oral regimen was shown to be effective and well tolerated in HIV/HCV-coinfected patients receiving ART.
Coadministration of GS-9669 or GS-9451 with sofosbuvir/ledipasvir was well tolerated and allowed the therapy duration to be shortened from 12 weeks to 6 weeks while maintaining virologic efficacy.
Interferon/RBV-free regimen comprising 3 direct-acting antiviral agents plus RTV was well tolerated and highly effective in a phase III trial conducted in therapy-naive noncirrhotic patients with genotype 1b HCV monoinfection.
Effects of statin use on CD4+ cell recovery were observed across CD4+ cell count categories and were greatest after previous virologic failure.
In this longitudinal study, the incidence of new-onset depression was significantly higher among antiretroviral-treated patients with persistent HIV-1 RNA detected in CSF
Protective effect of GSK744 LA observed despite low vaginal:plasma concentration ratio.
Lower rate of discontinuations due to adverse events with DTG-based regimen and no INST or NRTI resistance in patients with virologic failure of this regimen.
Switching to the single-tablet regimen was associated with a higher rate of virologic suppression at Week 48 and was well tolerated.
Switching to the single-tablet INSTI regimen was associated with consistently higher rates of virologic suppression and adverse events similar to those reported in earlier clinical studies when compared with regimens consisting of an NNRTI plus FTC/TDF.
In ART-treated patients, time-updated viremia copy-years better predicts mortality vs most recent HIV-1 RNA level
From 2000-2013, the frequency of resistance associated mutations in HIV-1 integrase remained low in treatment-naive patients recruited to clinical trials.
Women treated with efavirenz in pregnancy experienced greater likelihood of virologic suppression than women treated with lopinavir/ritonavir, although both regimens were highly effective in preventing HIV transmission.
Early ART initiation and virologic suppression was associated with depletion of the proviral reservoir in a cohort of perinatally HIV-infected youths.
The reduced risk of MI in the HIV-infected population in recent years may be due to factors such as improvements in antiretroviral drug lipid effects, improvements in cardiovascular risk factors, and reductions in immunodeficiency.
The association between abacavir use and risk of MI remained evident through continued follow-up despite decreasing prescription of abacavir to patients with elevated CVD risk.
Normalization of CD4/CD8 ratio infrequent in patients initiating ART, but more common in younger patients, at higher CD4+ cell count, and with more recent ART initiation.
Baseline markers of inflammation, immune activation independently associated with greater bone loss.
Secondary analysis of the VOICE study finds significant association between method of injectable contraception and HIV acquisition risk.
Safety profile was comparable between the 2 regimens, but resistance at failure was more common with the raltegravir-based regimen
All regimens similar in time to virologic failure, but RAL superior to both PIs and DRV/RTV superior to ATV/RTV in composite efficacy and tolerability endpoint.
Sensitive screening finds transmission frequency of key resistance mutations is 70% higher than previously estimated by conventional genotyping.
Treatment-naive patients experienced fewer adverse events and had comparable virologic suppression rates to efavirenz-based regimens with regimens containing investigational oral integrase inhibitor over a 48-week study period.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.